Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$887.16 USD

887.16
1,970,679

+1.61 (0.18%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $884.12 -3.04 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Up on $1.1B Research Deals With 2 Biotechs

Novo Nordisk (NVO) gains 4% after signing $1.1 billion research collaboration agreements with two biotech companies to develop novel treatment approaches for cardiometabolic diseases.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's New Digital Pharmacy, NVO & ABBV's Fresh R&D Deals

Eli Lilly (LLY) launches a new direct-to-consumer website to provide easy access to its medicines. Novo Nordisk (NVO) announces two research collaborations to develop novel treatments for cardiometabolic diseases.

Eli Lilly (LLY) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Eli Lilly (LLY) closed at $614.50, marking a -0.52% move from the previous day.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Sheraz Mian headshot

Top Research Reports for Amazon.com, Berkshire Hathaway & Eli Lilly

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Berkshire Hathaway Inc. (BRK.B) and Eli Lilly and Company (LLY).

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly (LLY) Stock Up 57% in 2023: Will the Uptrend Continue?

Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.

Eli Lilly (LLY) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw Eli Lilly (LLY) settling at $580.85, representing a -0.11% change from its previous close.

Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday

Fusion Pharmaceuticals (FUSN) surges to a new record level 52-week high after analysts at Raymond James upgraded its rating following the buyout announcements for two comparable companies.

Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?

Smart Beta ETF report for QUS

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

Style Box ETF report for FTCS

Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?

Style Box ETF report for USMV

Eli Lilly (LLY) Rises Yet Lags Behind Market: Some Facts Worth Knowing

The latest trading day saw Eli Lilly (LLY) settling at $572, representing a +0.31% change from its previous close.

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK

Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.

Kinjel Shah headshot

5 Big Drug Stocks That May Continue to Outperform in 2024

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know

Eli Lilly (LLY) closed at $572.04 in the latest trading session, marking a -0.28% move from the prior day.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

LLY Down as Patients Regain Weight After Stopping Zepbound

Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.